Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
Lenovo Revenue Surges 43% as AI Demand Drives Record First-Quarter Growth 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
Maersk Raises 2026 Earnings Outlook as Shipping Profits Beat Expectations 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Add as a preferred source on Google
CAMBRIDGE, Mass., Feb. 28, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Cowen and Company 37th Annual Health Care Conference. The presentation is scheduled for Tuesday, March 7th at 10:40 a.m. ET.
The webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
